Mysterious metformin

Oncologist

Volumn 14, Issue 12, 2009, Pages 1178-1181

  Chong, Curtis R ^a   Chabner, Bruce A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ANTINEOPLASTIC AGENT; ARSENIC; BUFORMIN; DOXORUBICIN; INSULIN; METFORMIN; PHENFORMIN; RETINOIC ACID; SULFONYLUREA DERIVATIVE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER STEM CELL; COLON CANCER; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; GLUCONEOGENESIS; HUMAN; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER CANCER; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; OVARY POLYCYSTIC DISEASE; OXIDATIVE PHOSPHORYLATION; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; RISK;

EID: 75449089570     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0286     Document Type: Note

References (46)

1. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-380.
2. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005;92:2076-2083.
3. Friberg E, Orsini N, Mantzoros CS et al. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia 2007;50:1365-1374.
4. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121:856-862.
5. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97:1679-1687.
6. Larsson SC, Orsini N, Brismar K et al. Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia 2006;49:2819 -2823.
7. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin's lymphoma: A meta-analysis of observational studies. Diabetes Care 2008;31: 2391-2397.
8. Vigneri P, Frasca F, Sciacca L et al. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123.
9. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 2008;300:2754-2764.
10. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304 -1305.
11. Duncan BB, Schmidt MI. Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research. Diabetes Care 2009;32:1748-1750.
12. Libby G, Donnelly LA, Donnan PT et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
13. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766 -1777.
14. Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254 -258.
15. Li D, Yeung SC, HassanMMet al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482- 488.
16. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control 2009;20:1617-1622.
17. Jonasson JM, Ljung R, TalbäckMet al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-1754.
18. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52:1732-1744.
19. Pocock SJ, Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet 2009;374:511-513.
20. Rosenstock J, Fonseca V, McGill JB et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-1973.
21. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765.
22. Ehninger G, Schmidt AH. Putting insulin glargine and malignancies into perspective. The Oncologist 2009;14:1169-1174.
23. de Miguel-Yanes JM, Meigs JB. When "flawed" translates into "flood": The unproven association between cancer incidence and glargine insulin therapy. The Oncologist 2009;14:1175-1177.
24. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-3302.
25. Muti P, Berrino F, Krogh V et al. Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle 2009;8:2661.
26. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A et al. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 2009;18:701-705.
27. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
28. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607- 614.
29. Koo SH, Flechner L, Qi L et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005;437:1109-1111.
30. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 2007;174:49-53.
31. Ji H, Ramsey MR, Hayes DN et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807- 810.
32. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-1646.
33. Ben Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-3586.
34. Gotlieb WH, Saumet J, Beauchamp MC et al. In vitro metformin antineoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110: 246-250.
35. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinasedependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269-10273.
36. Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008;3:18.
37. Liu B, Fan Z, Edgerton SM et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-2040.
38. Glucophage® package insert. Princeton, NJ: Bristol-Myers Squibb, 2009. Available at http://packageinserts.bms.com/pi/pi-glucophage.pdf, accessed December 4, 2009.
39. Kisfalvi K, Eibl G, Sinnett-Smith J et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:6539-6545.
40. Buzzai M, Jones RG, Amaravadi RK et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745- 6752.
41. Huang X, Wullschleger S, Shpiro N et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-221.
42. Schneider MB, Matsuzaki H, Haorah J et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270.
43. Hirsch HA, Iliopoulos D, Tsichlis PN et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-7511.
44. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108: 1105-1107.
45. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574 -579.
46. Nestler JE. Metformin in the treatment of infertility in polycystic ovarian syndrome: An alternative perspective. Fertil Steril 2008;90:14 -16.